|
Année 2009 |
|
|
Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates.
Daubriac J., Fleury-Feith J., Kheuang L., Galipon J., Saint-Albin A., Renier A., Giovannini M., Galateau-Sallé F. and Jaurand, M.C.
Cell Death and Differentiation, 2009, doi:10.1038/cdd.2009.32
Do asbestos and carbon nanotubes pose the same healt risk ?
Jaurand M.C., Renier A., Daubriac, J.
Part Fibre Toxicol, 2009, 6:16doi:10.1186/1743-8977-6-16.
|
|
|
|
Année 2008 |
|
|
Rapport de groupe d’experts
Les fibres minérales artificielles siliceuses. Fibres céramiques réfractaires - Fibres de verre à usage spécial. Évaluation de l’exposition de la population générale et des travailleurs
AFSSET. http://www.afsset.fr/index.php?pageid=671&parentid=619.
Dernière liaison 10 mai 2008
Sous presse
Mesothelial Cells
Jaurand M.C., Fleury-Feith J.
Textbook of Pleural Diseases, Second edition. Edited by Light & Lee, Oxford University Presse
Biologie de la plèvre
Fleury-Feith J., Jaurand M.C.
Traité de Pneumologie, Flammarion |
|
|
|
Année 2007 |
|
|
Clinico-pathological features and somatic gene alterations in refactory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.
Andujar P., Lecomte C., Renier A., Fleury-Feith J., Kheuang L., Daubriac J., Janin A., Jaurand M.C.
Carcinogenesis 2007, 28 : 1599-1605
Eighth international mesothelioma interest group.
Carbone M., Albelda S.M., Broaddus V.C., Flores R.M., Hillerdal G., Jaurand M.C., Kjaerheim K., Pass H.I., Robinson B., Tsao A.
Oncogene, 2007, 26:6959-67
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
Scherpereel A., French Speaking Society for Chest Medicine (SPLF) Experts Group. J. Ameille, P. Astoul, A. Bergeret, T. Berghmans, G. Bonardel, J.M. Brechot, P. Brochard, M.C. Copin, B. Crestani, G. Dabouis, A.Y. Delajartre, M. Derzelle, Fournier, A. Fraticelli, F. Galateau-Salle, R. Giudicelli, P. Godard, F. Grassin, M. Gregoire, L. Greillier, D Grunenwald, J. Guigay, C. Hennequin, B. Housset, M.C. Jaurand, K. Kerrou, Y. Lajat, F. Laurent, F. Le Pimpec-Barthes, C. Le Pechoux, D. Lerouge, J. Margery, C.-H. Marquette, O. Menard, JL. Michaud, I. Monnet, J.F. Morere, F. Natali, J.-C. Meurice, J.C. Pairon, M. Perol, H. Porte, P. Poulain, G. Robinet, P. Ruffie, R. Salmi, A. Scherpereel, S. Trogrlic, J.M. Vignaud, V. Westeel, G. Zalcman.
Respir Med, 2007, 101:1265-1276
Etude critique du rôle des paramètres physiques dans l’activité biologique.
dans : Nanoparticules
Jaurand M.C.
2007, INRS. Edition-Fabrication Livres. EDP Sciences. pp 530-560. |
|
|
|
Année 2006 |
|
|
Clinico-pathological features of murine mesothelioma induced by natural or synthetic fibers.
Andujar P., Lecomte C., Renier A., Jaurand M.C., Fleury-Feith J.
Lung Cancer 2006, 54: S7
Anoikis resistance in malignant pleural mesothelioma cells.
Daubriac J, Fleury-Feith J., Jaurand M.C.
Lung Cancer 2006, 57: S24
Asbestos, chromosomal deletions and tumor suppressor gene alterations in human malignant mesothelioma.
Jaurand M.C.
Lung Cancer 2006, 54: S15
How to assess asbestos exposure and identify a population at risk ?
Pairon J.C., Jaurand M.C., Laurent F., Salmi R., Astoul P., Galateau-Sallé F., Brochard P.
Rev Mal Respir, 2006, 23(4 Pt 3):11S9-27
|
|
|
|
Année 2005 et antérieures |
|
|
Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma.
Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC.
Cell Cycle. 2005 Dec;4(12):1862-9
Biomarkers in risk assessment of asbestos exposure.
Bhattacharya K, Dopp E, Kakkar P, Jaffery FN, Schiffmann D, Jaurand MC, Rahman I, Rahman Q.
Mutat Res. 2005 Nov 11;579(1-2):6-21
Pathogenesis of malignant pleural mesothelioma.
Jaurand MC, Fleury-Feith J.
Respirology. 2005 Jan;10(1):2-8.
Mesothelioma pathogenesis, facts and expectations.
Jaurand MC.
Pathol Biol (Paris). 2005 Feb;53(1):41-4.
Lectin-based three-color flow cytometric approach for studying cell surface glycosylation changes that occur during apoptosis.
Batisse C, Marquet J, Greffard A, Fleury-Feith J, Jaurand MC, Pilatte Y.
Cytometry A. 2004 Dec;62(2):81-8.
Mutations in TP53, but not FGFR 3, in urothelial cell carcinoma of the bladder are influenced by smoking : contribution of exogenous versus endogenous carcinogens.
Wallerand H., Bakkar A.A., De Medina S.G., Pairon J.C., Yang Y.C., Vordos D., Bittard H., Fauconnet S., Kouyoumdjian J.C., Jaurand M.C., Zhang Z.F., Radvanyi F., Thiery J.P., Chopin D.K.
Carcinogenesis, 2005, 26:177-184
Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAID) on human urological tumor cell lines.
Huguenin S., Vacherot F., Fleury-Feith J., Riffaud J.P., Chopin D.K., Bolla M., Jaurand M.C.
Cancer Lett, 2005, 218:163-170
|
Grow, differentiation and senescence of normal human urothelium in organ-like culture.
Daher A, De Boer Wi, Le Frere-Belda Ma, Kheuang L, Abbou Cc, Radvanyi F, Jaurand Mc, Thiery Jp, Gil Diez De Medina S, Chopin Dk.
Eur Urol, 2004, 45(6):799-805.
Nitrosulindac (NCS 1102), a new nitric oxide-donating non steroidal antiinflammatory drug (NO-SAIDS), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines.
Huguenin S., Fleury-Feith J., Kheuang L., Jaurand M.C., Bolla M., Riffaud J.P., Chopin D., Vacherot F.
The Prostate, 2004, 61:132-141.
Gene expression profiles in human mesothelioma cell lines in response to IFNγ treatment.
Kettunen E., Vivo C., Gattacceca F., Knuutila S., Jaurand M.C.
Cancer Genet Cytogenet, 2004, 152:42-51.
|
Transfer into a mesothelioma cell line of tumor suppressor gene p16 by cholesterol-based cationic lipids.
Piperno-Neumann S., Oudar O., Reynier P., Briane D., Cao A., Jaurand M.C., Naejus R., Kraemer M., Breau J.L., Taillandier E.
Biochim Biophys Acta, 2003, 78449:1-9
Cell cycle checkpoint status in human malignant mesothelioma cell lines : response to gamma radiation.
Vivo C., Lecomte C., Levy F., Leroy K., Kirova Y., Renier A., Kheuang L., Piedbois P., Chopin D., Jaurand M.C.
Br J Cancer, 2003, 88:388-3957.
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Bakkar A.A., Wallerand H., Radvanyi F., Lahaye J.B., Pissard S., Lecerf L., Kouyoumdjian J.C., Abbou C.C., Pairon J.C., Jaurand M.C., Thiery J.P., Chopin D.K., De Medina S.G.
Cancer Res. 2003, 63:8108-8112.
|
Ad-IFN-gamma antiproliferative and antitumoral responses in malignant mesothelioma.
Gattacceca F., Pilatte Y., Billard C., Monnet I., Moritz S., Le Carrou J., Eloit M., Jaurand M.C.
Clin Cancer Res, 2002, 8:3298-3304.
Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinase.
Harvey P., Clark I.M., Jaurand M.C., Warn R.M., Edwards D.R.
Br J Cancer, 2000, 83:1147-1153.
Absence of SV40 large T antigen in human mesothelioma cell lines.
Pilatte Y., Vivo C., Renier A., Kheuang L., Greffard A., Jaurand M.C.
Am J Resp Cell Mol Biol, 2000, 23:788-793
|
|
|
|
Les publications récentes 
